Iovance Biotherapeutics (IOVA) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 486.3% versus a gain of 3.5%. Over five years, TARS leads with a +153.2% price change compared with -50.0% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($6.62 billion vs $3.42 billion), about 1.9 times the size, while Tarsus Pharmaceuticals is growing revenue faster (+146.7% vs +60.6%).
Tarsus Pharmaceuticals converts more of its revenue into profit, with a net margin of -14.7% versus -148.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IOVA | TARS |
|---|---|---|
| Share price | $14.62 | $73.16 |
| Market cap | $6.62B | $3.42B |
| 1-day change | +9.84% | +1.30% |
| YTD return | +387.55% | -11.80% |
| 1-year return | +486.34% | +3.54% |
| 5-year return | -49.98% | +153.23% |
| EPS (TTM) | $-0.69 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $263.50M | $451.36M |
| Revenue growth (YoY) | +60.60% | +146.71% |
| Net income (latest FY) | $-390.98M | $-66.42M |
| Gross margin | 34.28% | — |
| Operating margin | -153.08% | -15.72% |
| Net margin | -148.38% | -14.72% |
| 52-week high | $15.30 | $91.53 |
| 52-week low | $1.76 | $53.89 |
| Distance from 52-week high | -4.44% | -20.07% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -12.45% | +36.00% |
| Average volume | 17.82M | 870.50K |
| Shares outstanding | 452.97M | 46.79M |
| Employees | 975 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed TARS by 482.8 percentage points over the past year.
- Tarsus Pharmaceuticals is more profitable, keeping -14.7 cents of every revenue dollar as net income versus -148.4 cents for Iovance Biotherapeutics.
- Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs +60.60%).
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
IOVA vs TARS FAQ
Which is bigger, Iovance Biotherapeutics or Tarsus Pharmaceuticals?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $6.62B compared with $3.42B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, IOVA or TARS?
IOVA returned +486.34% over the past 12 months, compared with +3.54% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Iovance Biotherapeutics and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.